Addison’s disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:29:01 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Addison’s disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Modified-Release Hydrocortisone vs. Immediate-Release Hydrocortisone for Patients with Addison’s Disease https://clinicaltrials.eu/trial/study-on-the-effects-of-modified-release-hydrocortisone-vs-immediate-release-hydrocortisone-for-patients-with-addisons-disease/ Wed, 29 Apr 2026 14:23:57 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-modified-release-hydrocortisone-vs-immediate-release-hydrocortisone-for-patients-with-addisons-disease/ This clinical trial is focused on studying the effects of a medication called Efmody on patients with Addison’s Disease. Addison’s Disease is a condition where the body does not produce enough of certain hormones, which can lead to symptoms like fatigue, muscle weakness, and weight loss. The study will compare the effects of Efmody, a modified-release form of hydrocortisone, with immediate-release hydrocortisone, which is commonly used as a replacement therapy for this condition.

The purpose of the study is to evaluate how switching from immediate-release hydrocortisone to Efmody affects patients’ quality of life, sleep efficiency, and daily stability. The study will also assess changes in the timing of melatonin release, which is a hormone that helps regulate sleep. Participants will take part in a cross-over study, meaning they will receive both treatments at different times during the study. This approach allows researchers to directly compare the effects of the two treatments on the same group of patients.

Throughout the study, participants will be monitored for changes in their quality of life using specific questionnaires designed for people with Addison’s Disease. The study will last for several weeks, with each treatment period lasting 11 weeks. By the end of the study, researchers hope to gain a better understanding of how Efmody can improve the management of Addison’s Disease and enhance the overall well-being of patients.

]]> Stowarzyszenie na rzecz osób z chorobą Addisona i niedoczynnością nadnerczy https://clinicaltrials.eu/organisation/stowarzyszenie-na-rzecz-osob-z-choroba-addisona-i-niedoczynnoscia-nadnerczy/ Wed, 29 Apr 2026 13:34:19 +0000 https://clinicaltrials.eu/organisation/stowarzyszenie-na-rzecz-osob-z-choroba-addisona-i-niedoczynnoscia-nadnerczy/ The Association for People with Addison’s Disease and Adrenal Insufficiency was established to support individuals affected by these rare conditions, as well as their families and caregivers. The organization focuses on promoting health, raising awareness about Addison’s disease and other forms of adrenal insufficiency, and carrying out educational activities aimed both at patients and at medical and social communities.

]]>